DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0276182 A1 Baker, JR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0276182 A1 Baker, JR US 20120276.182A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0276182 A1 Baker, JR. et al. (43) Pub. Date: Nov. 1, 2012 (54) METHODS OF TREATING FUNGAL, YEAST Publication Classification AND MOLD INFECTIONS (51) Int. C. Inventors: James R. Baker, JR. Ann Arbor, A6II 47/44 (2006.01) (75) A6II 3/53 (2006.01) MI (US); Mary R. Flack, Ann A638/12 (2006.01) Arbor, MI (US); Susan M. Ciotti, A63L/7048 (2006.01) Ann Arbor, MI (US); Joyce A. A 6LX 9/07 (2006.01) Sutcliffe, West Newton, MA (US) A63L/464 (2006.01) (73) Assignee: Nanobio Corporation A 6LX 3/5.375 (2006.01) B82Y5/00 (2011.01) (21) Appl. No.: 13/544,789 (52) U.S. C. ......... 424/405; 514/784: 514/785: 514/396; (22) Filed: Jul. 9, 2012 514/399; 514/274: 514/231.2: 514/3.6; 514/31; 977/700; 977/906 Related U.S. Application Data (63) Continuation of application No. 12/430,700, filed on (57) ABSTRACT Apr. 27, 2009, now Pat. No. 8,226,965. The present invention relates to methods for treating and (60) Provisional application No. 61/048.075, filed on Apr. completely curing fungal, yeast, and/or mold infections in 25, 2008, provisional application No. 61/129,962, human Subjects comprising topically administering to a filed on Aug. 1, 2008, provisional application No. human Subject in need thereof an antifungal nanoemulsion 61/115,879, filed on Nov. 18, 2008. composition. Patent Application Publication Nov. 1, 2012 Sheet 1 of 26 US 2012/0276182 A1 go as g 9. & as3 E2 O 8 ... C 92 .9 Es of a D -N4St So of OR oS2 O.s : C C 2 Cls -- Z. Cld g:2 w- . D Ut sma ... O SD- Cl2 g's55 O O) L Patent Application Publication Nov. 1, 2012 Sheet 2 of 26 US 2012/0276182 A1 uo|s|nueOueN:Z?un61 uÞISO?u,ÁIÐA||9C] Patent Application Publication Nov. 1, 2012 Sheet 3 of 26 US 2012/0276182 A1 *·**** ?ºff? * Á??ueqsisuoOeuesuo?s|nuuaoueN"9eun61-I 88: 3 & &$&&! ***************************{{?$3&&&#####$$3&&3&&3&&***** «&& **** ?*)(????????**?. i8::::3838 Patent Application Publication Nov. 1, 2012 Sheet 4 of 26 US 2012/0276182 A1 ************** uogovgousque?oøw.tzeun61 &&&&&&&& Patent Application Publication Nov. 1, 2012 Sheet 5 of 26 US 2012/0276182 A1 Patent Application Publication Nov. 1, 2012 Sheet 6 of 26 US 2012/0276182 A1 ????,wz?*****8?23. ##§§§§§?o~~~~~~~~~~~~~~~~~~~4.ºž **???????w?ºs???x**********??ggaez?)*******&****************3×4gººg»z?, ?*****9***???æg -orz §§§} ten peoeyeun Patent Application Publication Nov. 1, 2012 Sheet 8 of 26 US 2012/0276182 A1 euogsøgesauno?eoibo?ooÁINjouosqueduuoo;ºaumôia oe?uedpue(„z00-aNA)uorsinuaouen 838: 88: 8::::::: Patent Application Publication Nov. 1, 2012 Sheet 9 of 26 US 2012/0276182 A1 Patent Application Publication Nov. 1, 2012 Sheet 10 of 26 US 2012/0276182 A1 Patent Application Publication Nov. 1, 2012 Sheet 11 of 26 US 2012/0276182 A1 9?uosuo|s|nuuaoueN?o?oeduul'OLeun61 unuqnu'IgoÁl]]|qe?A Patent Application Publication Nov. 1, 2012 Sheet 12 of 26 US 2012/0276182 A1 Patent Application Publication Nov. 1, 2012 Sheet 13 of 26 US 2012/0276182 A1 Patent Application Publication Nov. 1, 2012 Sheet 14 of 26 US 2012/0276182 A1 SunOHvZ?euDISuenepeO is & is 8 x g :: * ueuunHo?u?KuêA||3C]uoIsInuuboueN.9||eun61 ess tuff it Patent Application Publication Nov. 1, 2012 Sheet 15 of 26 US 2012/0276182 A1 uoasocluo|s|nuaoueN?o?oe??E:7).?un61– sunoHVZ?eupIS6ldo?u,Kuan||eG Patent Application Publication Nov. 1, 2012 Sheet 17 of 26 US 2012/0276182 A1 Patent Application Publication US 2012/0276182 A1 sunouvzqesquuep?daupisau?wsu?a?ozeuoo?W?osla^aT'LLaun61-I '(GIIG)uo?eo||dde||eo!do!Jage Patent Application Publication Nov. 1, 2012 Sheet 19 of 26 US 2012/0276182 A1 '81,aun612 Patent Application Publication Nov. 1, 2012 Sheet 20 of 26 US 2012/0276182 A1 zuuoIzºg:eeuw6u?soqlejno zuuo£'C:eeuwalpp?W zuuoG’O:eeuwuauu! Patent Application Publication Nov. 1, 2012 Sheet 21 of 26 US 2012/0276182 A1 dogsurtoqþz?epaaotuðuupis Odogot?o?ëü?tä???äp Ápn?Suo?sn???qIeua?eI:Ozaun61-I upISuenepeoueuunHu? ?aaepeouetun?? Patent Application Publication Nov. 1, 2012 Sheet 22 of 26 US 2012/0276182 A1 g?z6+ 8388: 8: 88 SunoHVZ?eupISS?uuJep?d?J?AepeO ueuunHo?u?uo|sn?G|eJe?eT:LZ?un61 uo?sinuaoueN%9'00dOdeHºo??N%9’ ########&g ? 88: 8:::::::: 88 Patent Application Publication Nov. 1, 2012 Sheet 23 of 26 US 2012/0276182 A1 ønssil?eurapidau??,uo?sinuaoueNgoquodsueu1:zzaun612 ;*,**,***** K: sm ess tie. frt Patent Application Publication Nov. 1, 2012 Sheet 24 of 26 US 2012/0276182 A1 s: 888; i.e. f is fit Patent Application Publication Nov. 1, 2012 Sheet 25 of 26 US 2012/0276182 A1 tire fift is Patent Application Publication Nov. 1, 2012 Sheet 26 of 26 US 2012/0276182 A1 sunouºzstuuuedu?ulina(Odo)uo?sinuaoueN.gzºdnôl uo?eo?idde-isod US 2012/0276.182 A1 Nov. 1, 2012 METHODS OF TREATING FUNGAL YEAST another term for dermatophyte infections of the nail. Second AND MOLD INFECTIONS ary bacterial infections may develop from the fungal infec tion. CROSS-REFERENCE TO RELATED 0005 Tinea is very common, especially among children, APPLICATIONS and may be spread by skin-to-skin contact, as well as via 0001. This application is a continuation of U.S. patent contact with contaminated items such as hairbrushes or application Ser. No. 12/430,700, filed Apr. 27, 2009, which through the use of the same toilet seat as an infected indi claims priority of U.S. Provisional Patent Application No. vidual. Tinea spreads readily, as those infected are contagious 61/048,075, filed on Apr. 25, 2008; U.S. Provisional Patent even before they show symptoms of the disease. Participants Application No. 61/129,962, filed on Aug. 1, 2008; and U.S. in contact sports Such as wrestling have a risk of contracting Provisional Patent Application No. 61/115,879, filed on Nov. the fungal infection through skin-to-skin contact. 18, 2008. The contents of these applications are incorporated 0006 Tinea is mildly contagious. Tinea is also a common herein by reference in their entirety. infection in domestic animals, especially farm animals, dogs and cats and even Small pets like hamsters or guinea pigs. FIELD OF INVENTION Humans can contract tinea (also commonly referred to as “ringworm”) from these animals as humans are in close con 0002 The present invention relates to methods for treat tact with them. Tinea can also be caught from other humans, ing, killing, and/or inhibiting the growth of fungal, yeast, and both by direct contact and by prolonged contact with flakes of mold pathogens in human Subjects comprising topically shed skin (from sharing clothes or from house dust, for administering to a human Subject in need thereofa nanoemul instance). sion composition having antifungal, anti-yeast, and/or anti 0007. The best known sign of tinea in people is the appear mold properties. The present invention also relates to meth ance of one or more red raised itchy patches with defined ods for treating, preventing, and/or completely curing fungal, edges, not unlike the herald rash of Pityriasis rosea. These yeast, and/or mold infections in human Subjects comprising patches are often lighter in the center, taking on the appear topically administering to a human Subject in need thereof a ance of a ring with hyperpigmentation around the circumfer nanoemulsion composition having antifungal, anti-yeast, ence caused by an increase in melanin. If the infected area and/or anti-mold properties. involves the scalp or beard area, then bald patches may become evident. The affected area may become itchy for BACKGROUND OF THE INVENTION periods of time. A. Fungal/Yeast/Mold Infections 0008. Sometimes a tinea infection may cause skin lesions 0003) Fungi cause a wide variety of diseases in humans. in a part of the body that is remote from the actual infection. While some fungi cause infections limited to the outermost Such lesions are called “dermatophytids'. The lesions them layers of the skin and hair (Superficial mycoses), other fungi selves are fungus-free, and normally disappear upon treat cause cutaneous mycoses by penetrating to the keratinized ment of the actual infection. The most common example is an layers of the skin, hair and nails and triggering pathologic eruption in the hands resulting from a fungus infection of the changes in the host. Subcutaneous mycoses cause infections feet. Dermatophytids are essentially a generalized allergic in the dermis, Subcutaneous tissues, muscle and fascia and are reaction to the fungus. often chronic. Systemic mycoses originate primarily in the 0009. Thus, fungi and yeast such as Microsporum species, lung and may cause secondary infections in other organ sys Trichophyton species, Epidermophyton species, and Candida tems in the body. Patients with immune system deficiencies species can cause persistent and difficult to treat infections. are often prone to opportunistic mycoses. 00.10 Examples of Microsporum species include M. canis 0004 Dermatophytes, including Trichophyton rubrum and M. gypseum. Microsporum is one of the several fungal and Trichophyton mentagrophytes, are responsible for fungal genera that cause dermatophytosis. Dermatophytosis is a infections of the skin or Dermatophytoses (dermatophytose). general term used to define the infection in hair, skin or nails Tinea pedis is a skin infection that most often manifests due to any dermatophyte species. Similar to other dermato between the toes, causing scaling, flaking and itching of the phytes, Microsporum has the ability to degrade keratin and affected skin. Blisters and cracked skin may also occur, lead thus can reside on skin and its appendages and remains non ing to exposed raw tissue, erythema, pain, Swelling and invasive.
Load more

Recommended publications
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Malassezia Furfur Folliculitis in Cancer Patients. the Need for Interaction Of
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 23, No. 5 Copyright © 1993, Institute for Clinical Science, Inc. Malassezia furfur Folliculitis in Cancer Patients The Need for Interaction of Microbiologist, Surgical Pathologist, and Clinician in Facilitating Identification by the Clinical Microbiology Laboratory* RAMON L. SANDIN, M.D., M.S.,f TZANN-TARN FANG, M.D.,* JOHN W. HIEMENZ, M.D.,t JOHN N. GREENE, M.D.,§ LINA CARD, M.T. (ASCP),t ALEXANDRA KALIK, M.D.,t and JENO E. SZAKACS, M.D.t Departments of Pathology, f Bone Marrow Transplant Service,t and Infectious Diseases,§ H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612-9497 ABSTRACT Malassezia furfur (MF) is a lipophilic yeast which can be found as a member of the indigenous microbiota of human skin. In immunocompro­ mised transplant patients, MF can cause a distinctive folliculitis which is a clinical look-alike to Candida folliculitis, the latter of more potentially devastating significance. Recovery of MF in culture is dependent upon the addition to culture media of an exogenous source of fatty acids, such as olive oil. The addition of an extra Sabourauds plate with an olive oil overlay to the routine set of media used to inoculate all skin biopsy specimens in order to detect MF is labor-intensive and not cost-effective. Thus, MF may not be isolated in cases of MF folliculitis unless the clinical microbiology laboratory is put on alert by the clinical suspicions of the attending physi­ cian, or by histopathologic findings suggestive of folliculitis revealed by review of surgical pathology slides.
    [Show full text]
  • WO 2009/132342 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132342 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/107 (2006.01) A61P 31/10 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (21) International Application Number: EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2009/04181 1 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 27 April 2009 (27.04.2009) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (25) Filing Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (26) Publication Language: English UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/048,075 25 April 2008 (25.04.2008) US kind of regional protection available): ARIPO (BW, GH, 61/129,962 1 August 2008 (01 .08.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/1 15,879 18 November 2008 (18.1 1.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant (for all designated States except US): ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, NANOBIO CORPORATION [US/US]; 23 11 Green MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), Road, Suite A, Ann Arbor, MI 48105 (US).
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • | Oa Tai Ei Rama Telut Literatur
    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Tinea Genitalis: a New Entity of Sexually Transmitted Infection? Case Series and Review of the Literature
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Tinea genitalis: a new entity of sexually transmitted infection? Case series and review of the literature Luchsinger, Isabelle ; Bosshard, Philipp Peter ; Kasper, Romano Silvio ; Reinhardt, Dominic ; Lautenschlager, Stephan Abstract: OBJECTIVE Investigation on recent cases of tinea genitalis after travelling to South East Asia. METHODS Patients with tinea in the genital region, which emerged after sex in South East Asia, underwent further assessment including microscopy, cultures and DNA analyses. RESULTS The case series includes seven patients. In six patients, Trichophyton interdigitale (former Trichophyton mentagrophytes) was detected. Three patients suffered from a severe inflammatory reaction of thesoft tissue and two of them needed hospitalisation due to severe pain. In four patients, cicatrising healing was noticed. Five patients were declared incapacitated for work. CONCLUSIONS Sexual activity should be considered as a potentially important and previously underappreciated means of transmission of T. interdigitale. To avoid irreversible scarring alopecia, prompt initiation of antifungal treatment is essential and adequate isolation and identification of the pathogen is mandatory. DOI: https://doi.org/10.1136/sextrans-2015-052036 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-113887 Journal Article Published Version Originally published at:
    [Show full text]
  • Young Adults Young Adults (20 - 35 Years)
    YOUNG ADULTS YOUNG ADULTS (20 - 35 YEARS) A large number of skin diseases reach their peak of expression during the young adult years, and these individuals also represent a large and growing proportion of the South African population, in common with other developing countries. Young adults are especially distressed by skin conditions that are uncomfortable, disfiguring or contagious. This group has also been severely affected by HIV/AIDS, with a consequent increase in the frequency and severity of the HIV- associated dermatoses. Some of these conditions have been discussed in other sections of this review. ACNE KELOIDALIS Inflammatory papules and pustules located mainly on the nape of the neck and occiput characterise this acne-like condition. It primarily affects black males. The lesions heal with scarring, creating huge keloids if this tendency exists. The cause is unknown, and unlikely to result from repeated shaving or short hair cutting. It DENGA A MAKHADO may be caused by unusually thick collagen, which traps and disrupts terminal MB ChB, FCDerm (SA) hair follicles. Treatment is not very successful, and large keloids are best excised Consultant Dermatologist by a surgeon. Mild cases can be helped by intralesional injection of steroids like Division of Dermatology Celestone Soluspan into individual papules and scars. Long-term oral tetracy- clines, as for acne, can also be beneficial, as can topical antibiotics like erythro- University of the Witwatersrand and mycin and clindamycin. Chris Hani Baragwanath Hospital Johannesburg ACNE VULGARIS Denga Anna Makhado is a consultant der- There has been a recent tendency for acne to persist beyond the teens, or even matologist at Chris Hani Baragwanath occur for the first time in adulthood, called persistent adult acne.
    [Show full text]
  • In Fungi and Their Interactions
    IN FUNGI AND THEIR INTERACTIONS Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform George Tegos, Tianhong Dai, Beth B Fuchs, Jeffrey J Coleman, Renato Araujo Prates, Christos Astrakas, Tyler G St Denis, Martha S Ribeiro, Eleftherios Mylonakis and Michael R Hamblin Journal Name: Frontiers in Microbiology ISSN: 1664-302X Article type: Review Article Received on: 15 Jan 2012 Accepted on: 13 Mar 2012 Provisional PDF published on: 13 Mar 2012 Frontiers website link: www.frontiersin.org Citation: Tegos G, Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St denis TG, Ribeiro MS, Mylonakis E and Hamblin MR(2012) Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front. Microbio. 3:120. doi:10.3389/fmicb.2012.00120 Article URL: http://www.frontiersin.org/Journal/Abstract.aspx?s=727& name=fungi%20and%20their%20interactions&ART_DOI=10.3389 /fmicb.2012.00120 (If clicking on the link doesn't work, try copying and pasting it into your browser.) Copyright statement: © 2012 Tegos, Dai, Fuchs, Coleman, Prates, Astrakas, St denis, Ribeiro, Mylonakis and Hamblin. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. This Provisional PDF corresponds to the article as it appeared upon acceptance, after rigorous peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform Tianhong Dai,1,2 Beth B.
    [Show full text]
  • Evidence-Based Danish Guidelines for the Treatment of Malassezia- Related Skin Diseases
    Acta Derm Venereol 2015; 95: 12–19 SPECIAL REPORT Evidence-based Danish Guidelines for the Treatment of Malassezia- related Skin Diseases Marianne HALD1, Maiken C. ARENDRUP2, Else L. SVEJGAARD1, Rune LINDSKOV3, Erik K. FOGED4 and Ditte Marie L. SAUNTE5; On behalf of the Danish Society of Dermatology 1Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2 Unit for Mycology, Statens Serum Institut, 3The Dermatology Clinic, Copen- hagen, 4The Dermatology Clinic, Holstebro, and 5Department of Dermatology, Roskilde Hospital, University of Copenhagen, Denmark Internationally approved guidelines for the diagnosis including those involving Malassezia (2), guidelines and management of Malassezia-related skin diseases concerning the far more common skin diseases are are lacking. Therefore, a panel of experts consisting of lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspi- dermatologists and a microbiologist appointed by the ces of the Danish Society of Dermatology undertook a Danish Society of Dermatology undertook a data review data review and compiled guidelines for the diagnostic and compiled guidelines on the diagnostic procedures procedures and management of pityriasis versicolor, se- and management of Malassezia-related skin diseases. borrhoeic dermatitis and Malassezia folliculitis. Main The ’head and neck dermatitis’, in which hypersensi- recommendations in most cases of pityriasis versicolor tivity to Malassezia is considered to be of pathogenic and seborrhoeic dermatitis include topical treatment importance, is not included in this review as it is restric- which has been shown to be sufficient. As first choice, ted to a small group of patients with atopic dermatitis. treatment should be based on topical antifungal medica- tion.
    [Show full text]
  • Differential Diagnosis of the Scalp Hair Folliculitis
    Acta Clin Croat 2011; 50:395-402 Review DIFFERENTIAL DIAGNOSIS OF THE SCALP HAIR FOLLICULITIS Liborija Lugović-Mihić1, Freja Barišić2, Vedrana Bulat1, Marija Buljan1, Mirna Šitum1, Lada Bradić1 and Josip Mihić3 1University Department of Dermatovenereology, 2University Department of Ophthalmology, Sestre milosrdnice University Hospital Center, Zagreb; 3Department of Neurosurgery, Dr Josip Benčević General Hospital, Slavonski Brod, Croatia SUMMARY – Scalp hair folliculitis is a relatively common condition in dermatological practice and a major diagnostic and therapeutic challenge due to the lack of exact guidelines. Generally, inflammatory diseases of the pilosebaceous follicle of the scalp most often manifest as folliculitis. There are numerous infective agents that may cause folliculitis, including bacteria, viruses and fungi, as well as many noninfective causes. Several noninfectious diseases may present as scalp hair folli- culitis, such as folliculitis decalvans capillitii, perifolliculitis capitis abscendens et suffodiens, erosive pustular dermatitis, lichen planopilaris, eosinophilic pustular folliculitis, etc. The classification of folliculitis is both confusing and controversial. There are many different forms of folliculitis and se- veral classifications. According to the considerable variability of histologic findings, there are three groups of folliculitis: infectious folliculitis, noninfectious folliculitis and perifolliculitis. The diagno- sis of folliculitis occasionally requires histologic confirmation and cannot be based
    [Show full text]
  • Annular Skin Lesions
    Red & Scaly Rashes Helpful tips and tricks for every day practice Disclosures • None Aims • Review common dermatologic conditions that can sometimes look similar and be difficult to differentiate • Review patterns and clues to use when analyzing common derm conditions • Discuss treatment recommendations Photo: Bolognia et al. Photo: Bolognia et al. Photo: Bolognia et al. Atopic Dermatitis “The itch that rashes” • Typically presents in infancy or early childhood • Chronic waxing and waning course • Complex genetic disease with environmental influences • Significant pruritus Additional Clues • Dennie-Morgan lines • Keratosis pilaris • Hyperlinear palms • Allergic shiners (periorbital darkening) Atopic Dermatitis Treatment • Sensitive skin care • Avoidance of triggers • Topical anti-inflammatory +/- antihistamines • Topical corticosteroids • Topical calcineurin inhibitors • Phototherapy • Systemic anti-inflammatory Photo: Bolognia et al. “Dried river bed” Photo: http://avax.news/wow/The_dried_riverbed.html Asteatotic Eczema • Eczema craquele or winter itch • Dry, rough, scaly and inflamed skin… “dried river bed” • Shins, flanks, posterior axilla • Associated with aging, xerosis, low humidity, frequent bathing Asteatotic Eczema Treatment • Topical corticosteroid OINTMENT • Improvement noted within days • Transition to regular, daily emollient therapy • Advise pts to get something in a tub, not a pump bottle • mineral oil, plain vaseline, CeraVe cream or ointment, cetaphil cream • TAC ointment (454 g if adult with multiple sites) Photo: Bolognia et al. Photo: www.nationaleczema.org Nummular Dermatitis • Coin shaped eczematous lesions • Very pruritic Nummular Dermatitis Treatment • High to medium potency topical corticosteroids Topical Corticosteroids… …Simplified Class I (super potent) Class III (high potency) Class VI (low potency) Clobetasol 0.05% Triamcinolone 0.1% Desonide 0.05% ointment Note: Triamcinolone 0.1% cream is class IV Photo credit: Ross Reule, MD Photo: Bolognia et al.
    [Show full text]